2Nathan D M. Long-term complications of diabetes mellitus[J]. N Engl J Meg, 1993, 328(23) : 1676-1681.
3Gabbay K H. The sorbitol pathway and the complications of diabetes[J]. N Eagl J Meg, 1973, 288(16) : 831-836.
4Jaspan J B, Towle V L. Clinical studies with an aldose reduc-tase inhibitor in the autonomic and somatic neuropathies of di-abetes[J]. Metabolism, 1986, 35(Suppl, 1): 83-92.
5Foppiano M, Lombardo G. Worldwide pharmacovigiiance systems and tolrestat withdrawal[J]. Lancet, 1997, 349(9049): 399-400.
6Greene D, Arezzo J, Brown M. Dose-related effects of the aldose reductase inhibitor zenarestat on nerve sorbitol levels,nerve conduction velocity and nerve fiber density in human diabetic neuropathy[J]. Diabetes, 1996, 45(Suppl, 2): 9-12.
7Oates P J, Ellerly C A. Reversal of galactose-induced renal hyperperfusion in rats by aldose reductase inhibitor zopolre-stat[J]. Diabetologia, 1999, 42(Suppl, 1): Abst 1034.
8Pfeifer M A, Schumer M P, Gelber D A. Aldose reductase inhibitors: the end of an era or the need for different trial de-signs[J]?Diabetes, 1997, 46(Suppl, 2) : S82-89.
9Schmidt A M, Yan S D, Wautier J L, et al. Activation of receptor for advanced glycation end products. A mechanism for chrionic vascular dysfunction in diabetic vasculopathy and atherosclerosis[J]. Circ Res, 1999, 84(5): 489-497.
10Baynes J W, Thorpe S R. Role of oxidative stress in diabetic complications. A new perspective on an old peredigm[J]. Di-abetes, 1999, 48(1): 1-9.
3BONADONNA RC, CHRISTOPHK, TIMH, et al. Glucokinaseactivator RO4389620 improves plasma glucose concentrations, beta - cell function, en- dogenous glucose output and glucose utiliza - tion in patients with type 2 dia- betes. 2009 - 05 - 16.
4A multi - center, double - blind, randomized, placebo - controlled, dose - ranging phase II study to investigate , tulera - bility and pharmacokinetics of RO4389620 in patients with type 2diabetes mellitus treated with a stable dose of meffonnin. 2009 -05 - 16.
8Hansen KB, Knop FK, Holst JJ, et al. Treatment of type 2 diabe- tes with glucagon-like peptide-1 reeeptor agonists[J]. Int J of Clin Pract, 2009, 63(8): 1154-1160.
9Ahran B. GLP-1 for type 2 diabetes[J]. Exp Cell Res, 2011, 317 (9) : 1239-1Z45.
10Mullard A. 2010 FDA drug approvals[J]. Nat Rev Drug Diseov, 2011, 10(2): 82-85.
